张正, 张雅迪, 邵佳康, 赵卫红. 免疫检查点抑制剂治疗三阴性乳腺癌的研究进展[J]. 解放军医学院学报, 2022, 43(3): 354-359. DOI: 10.3969/j.issn.2095-5227.2022.03.020
引用本文: 张正, 张雅迪, 邵佳康, 赵卫红. 免疫检查点抑制剂治疗三阴性乳腺癌的研究进展[J]. 解放军医学院学报, 2022, 43(3): 354-359. DOI: 10.3969/j.issn.2095-5227.2022.03.020
ZHANG Zheng, ZHANG Yadi, SHAO Jiakang, ZHAO Weihong. Research advances in immune checkpoint inhibitors for triple negative breast cancer[J]. ACADEMIC JOURNAL OF CHINESE PLA MEDICAL SCHOOL, 2022, 43(3): 354-359. DOI: 10.3969/j.issn.2095-5227.2022.03.020
Citation: ZHANG Zheng, ZHANG Yadi, SHAO Jiakang, ZHAO Weihong. Research advances in immune checkpoint inhibitors for triple negative breast cancer[J]. ACADEMIC JOURNAL OF CHINESE PLA MEDICAL SCHOOL, 2022, 43(3): 354-359. DOI: 10.3969/j.issn.2095-5227.2022.03.020

免疫检查点抑制剂治疗三阴性乳腺癌的研究进展

Research advances in immune checkpoint inhibitors for triple negative breast cancer

  • 摘要: 乳腺癌已成为全球范围内发生率最高的恶性肿瘤。作为乳腺癌中预后最差的一种亚型,三阴性乳腺癌(triple negative breast cancer,TNBC)的传统治疗效果欠佳。近年来,免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)在TNBC的治疗中取得了突破性进展。本文归纳了近年来ICIs在TNBC领域的一些重要研究,以期探索ICIs在TNBC治疗中的发展方向及应用前景。

     

    Abstract: Breast cancer has become the most common malignant tumor in the world. As a subtype of breast cancer with the worst prognosis, traditional treatment is not effective in triple negative breast cancer (TNBC). In recent years, immune checkpoint inhibitors (ICIs) have made a breakthrough in the treatment of TNBC. This paper summarizes some important studies of ICIs in the treatment of TNBC in recent years, in order to explore the development and application prospect of ICIs in the treatment of TNBC.

     

/

返回文章
返回